Molecular biology was Bianca’s first love before she discovered the joys and challenges of investing. After spending some time at Swiss pharmaceuticals company Novartis.. More
In times of crisis it is often the case that innovation strives. This time, the biotech and pharma industry has stepped up, and it very much looks like it will deliver the goods.
Earlier this year, many thought it was unthinkable to develop a vaccine from scratch within less than 18 months. Through the work we do as investors we had been looking at messenger RNA (mRNA) for some years, and to us, if someone can develop a vaccine, it will be the companies that have worked for some time on this new drug/vaccine modality.
Indeed, today BioNTech and its partner, Pfizer announced that BNT162b2 (an mRNA for the SARS-CoV-2 spike protein) achieved success in the first interim analysis from their phase 3 study. This is a remarkable achievement.
In August last year, I met with the Chief Medical Officer of BioNTech at the company’s headquarters in Mainz, Germany and discussed the immune system, cancer and the upcoming initial public offering (IPO). We had been fortunate to invest pre-IPO and we were puzzled how little interest there was in this cancer mRNA company. Fast forward to today and the world could not be more different.
Here is a biotech that has worked 24/7 since the beginning of the year, prioritised vaccine development and made sure it has a strong partner to accelerate development, manufacturing and distribution. This is biotech and pharma at its best.
It comes down to science, people and funding - the key aspects we pay close attention to in our everyday search for new technologies and innovations.
For more information:
A more detailed explanation of mRNA can be found here: https://www.platinum.com.au/Insights-Tools/The-Journal/COVID-19-Demystifying-this-Frightening-Disease
A short video which features Bianca talking about a selection of biotech investments in the Platinum International Health Care Fund, including BioNTech, can be found here: https://www.platinum.com.au/Insights-Tools/The-Journal/Biotechs-Changing-the-Future-of-Health-Care
DISCLAIMER: Platinum Investment Management Limited ABN 25 063 565 006, AFSL 221935, trading as Platinum Asset Management (“Platinum”). This information is general in nature and does not take into account your specific needs or circumstances. You should consider your own financial position, objectives and requirements and seek professional financial advice before making any financial decisions.
Commentary reflects Platinum’s views and beliefs at the time of preparation, which are subject to change without notice. To the extent permitted by law, no liability is accepted by Platinum for any loss or damage as a result of any reliance on this information.
Tapping into Exaggerated Demise and Underappreciated Growth
Nintendo: Switching it up with Innovation
Video - Investing for the Long Haul
We use technologies, such as cookies, and process personal information, such as IP addresses and cookie identifiers,
to analyse traffic to our site, personalise advertisements and content based on your interests, measure the performance
of our advertisements and content, derive insights about the audiences who visit our site and see our advertisements
and content, and to build target audiences on social media. We share this information with our social media and analytics
service providers. Click on the adjacent button to consent to the use of this technology and the processing of your
Some cookies are needed to make our website work and can't be turned off. But we need your consent to use others that are not essential.
You can make your choices below and update them at any time from the 'Manage Cookies' link at the end of any page. Find out more in our
These cookies are needed to run our website, to keep it secure, and to obey regulations that apply to us.
These cookies remember your region or country, language, accessibility options and your settings. This also includes
things like your User ID on the logon page
These cookies tell us how customers use our website. We study and profile this data to help us improve our products and performance.
These cookies help us decide which products, services and offers may be relevant for you. We may use this data
to tailor the ads you see on our own and other websites and apps. We may also use this data to build target
audiences on social media.